Stephen Gitelman
University of California San Francisco, School of Medicine: Diabetes Center · Type 1 Diabetes TrialNet · University of California, San Francisco
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Stephen Gitelman as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 06:17 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT05574335 · Siplizumab in T1DMNational Institute of Allergy and Infectious Diseases (NIAID) · terminated · Type 1 Diabetes Mellitus · study chair
- Ph2NCT03929601 · Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 DiabetesNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · active not recruiting · Type 1 Diabetes Mellitus · study chair
- Ph2NCT00515099 · Study of Antithymocyte Globulin for Treatment of New-onset T1DMNational Institute of Allergy and Infectious Diseases (NIAID) · terminated · New-onset Type 1 Diabetes Mellitus · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 06:17 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Training Program in Pediatric EndocrinologyT32DK007161 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2013 to 2026 · $297,759 awarded in 2026Same name and institution; not confirmed by an ID
- Continuation of UCSF as a Clinical Center for TrialNetU01DK061010 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2001 to 2018 · $693,225 awarded in 2018Same name and institution; not confirmed by an ID
- K12 In Diabetes (KIDS)K12DK094726 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 2011 to 2015 · $354,974 awarded in 2015Same name and institution; not confirmed by an ID
- TRIALNET NATURAL HISTORY STUDY OF THE DEVELOPMENT OF TYPE 1 DIABETESM01RR001271 · NCRR · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 1995 to 2005 · $71,924 awarded in 2005Same name and institution; not confirmed by an ID
- VGR-1/BMP-6 AND CHONDROGENESIS AND OSTEOGENESISK08AR001897 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 1993 to 1997 · $83,988 awarded in 1997Same name and institution; not confirmed by an ID
- TRANSCRIPTIONAL REGULATION OF P450 C17 GENEF32DK008325 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · fiscal years 1989 · $31,750 awarded in 1989Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Data Coordinating Center for Type 1 Diabetes TrialNet (UC4)USF: TrialNet UC4-3UC4DK117009 · NIDDK · UNIVERSITY OF SOUTH FLORIDA · PI JEFFREY P KRISCHER · fiscal years 2017 to 2019Named on NCT03929601
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 06:17 UTC. The ranking covers the 200 most relevant of 38 PubMed records, and a shared surname and initials can bring in a namesake. All 38 on PubMed
- An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.N Engl J Med · 2019945 citationsRCR 36.0
- Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.N Engl J Med · 2002944 citationsRCR 17.4
- Type 1 diabetes immunotherapy using polyclonal regulatory T cells.Sci Transl Med · 2015909 citationsRCR 26.7
- Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.N Engl J Med · 2009865 citationsRCR 19.1
- 513 citationsRCR 10.4
- 498 citationsRCR 11.8
- 346 citationsRCR 9.0
- 309 citationsRCR 8.6
- 302 citationsRCR 7.2
- Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients.J Clin Invest · 2015255 citationsRCR 7.5